Clinical information

Restoril™ (temazepam) capsules

As a healthcare professional, you know the importance of a good night’s sleep. According to the National Sleep Foundation (NSF), two-thirds of Americans have sleep problems; 56% of adults reported experiencing symptoms of insomnia a few nights a week or more, yet only half of those people were being treated by a healthcare provider.¹

This is where you can make a difference.

Ask your patients about their sleeping behavior. Encourage your patients to keep a sleep diary and become aware of their sleep habits. We've provided information for your patients about insomnia and about Restoril™ (temazepam) capsules.

Important safety information: Restoril™ is indicated for the short-term treatment of insomnia (generally 7 to 10 days). The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Restoril™ is contraindicated in women who are pregnant or may become pregnant because of the potential risk to the fetus. The most common side effects of Restoril™ are drowsiness, dizziness, lightheadedness, and difficulty with coordination. Severe allergic reactions have been reported in patients taking sedative-hypnotics, including Restoril™. Complex behaviors such as “sleep driving” have also been reported. Although behaviors such as “sleep driving” may occur with Restoril™ alone at therapeutic doses, the use of alcohol or other CNS depressants with Restoril™ appears to increase the risk of these unusual behaviors, as does the use of Restoril™ doses exceeding the maximum recommended dose. Use extreme care while doing anything that requires complete alertness, such as driving a car, operating machinery, or piloting an aircraft.

Healthcare Provider Letter

For more information about Restoril™ (temazepam) capsules, please read the complete prescribing information.

For additional
information on
sleep disorders
visit the
National Sleep Foundation»